Search Result

Results for "

barrier function

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (2) Autophagy (1) Bacterial (1) Btk (1) c-Met/HGFR (1) Endogenous Metabolite (6) Ferroptosis (1) Formyl Peptide Receptor (FPR) (1) FXR (1) GABA Receptor (1) Histone Acetyltransferase (1) Influenza Virus (1) IRAK (1) Isotope-Labeled Compounds (2) LRRK2 (1) mAChR (1) Melanocortin Receptor (2) mGluR (1) Monoamine Oxidase (1) mTOR (1) Myosin (1) Na+/K+ ATPase (2) Necroptosis (1) NF-κB (1) P2Y Receptor (1) Potassium Channel (2) PROTACs (1) Proton Pump (2) Reactive Oxygen Species (3) STAT (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (7) Endocrinology (2) Infection (3) Inflammation/Immunology (9) Metabolic Disease (12) Neurological Disease (17)

By Targets:

Antibiotic (1)

Apoptosis (2)

Autophagy (1)

Bacterial (1)

Btk (1)

c-Met/HGFR (1)

Endogenous Metabolite (6)

Ferroptosis (1)

Formyl Peptide Receptor (FPR) (1)

FXR (1)

GABA Receptor (1)

Histone Acetyltransferase (1)

Influenza Virus (1)

IRAK (1)

Isotope-Labeled Compounds (2)

LRRK2 (1)

mAChR (1)

Melanocortin Receptor (2)

mGluR (1)

Monoamine Oxidase (1)

mTOR (1)

Myosin (1)

Na+/K+ ATPase (2)

Necroptosis (1)

NF-κB (1)

P2Y Receptor (1)

Potassium Channel (2)

PROTACs (1)

Proton Pump (2)

Reactive Oxygen Species (3)

STAT (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (7)

Endocrinology (2)

Infection (3)

Inflammation/Immunology (9)

Metabolic Disease (12)

Neurological Disease (17)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147296

Omesdafexor MET642	FXR	Inflammation/Immunology Cancer
Omesdafexor (MET642) is an oral FXR agonist. Omesdafexor can improve colitis induced by adoptive T cell transfer，promote intestinal antimicrobial function, barrier function and inhibit inflammation .

HY-160410

Ceramide 3B	Others	Neurological Disease Inflammation/Immunology
Ceramide 3B is a ceramide 3 lipid class with aggregation behavior. Ceramide 3B has a variety of physiological functions and can serve as a penetration enhancer and auxiliary emulsifier, playing an important role in barrier function stability .

HY-76201

Dexrazoxane hydrochloride 5+ Cited Publications ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride	Others	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a heart protectant that can help preserve ovarian function and fertility. Dexrazoxane hydrochloride has antioxidant and anti-inflammatory properties, can cross the blood-brain barrier, improves motor function disorders, and offers neuroprotective effects, making it useful in the study of neurodegenerative diseases .

HY-13813

Blebbistatin Maximum Cited Publications 20 Publications Verification	Myosin	Others
Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration .

HY-108295

Pivagabine CXB-722	GABA Receptor	Neurological Disease
Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain .

HY-N0729

Linoleic acid 10+ Cited Publications	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .

HY-11030

SNT-207858	Melanocortin Receptor	Metabolic Disease Endocrinology Cancer
SNT207858 is a selective, blood brain barrier penetrating, potent and orally active melanocortin-4 (MC-4) receptor antagonist. SNT207858 has an IC₅₀ of 22 nM (binding) and 11 nM (function) on the MC-4 receptor .

HY-11030A

SNT-207858 free base	Melanocortin Receptor	Metabolic Disease Endocrinology Cancer
SNT207858 free base is a selective, blood brain barrier penetrating, potent and orally active melanocortin-4 (MC-4) receptor antagonist. SNT207858 free base has an IC₅₀ of 22 nM (binding) and 11 nM (function) on the MC-4 receptor .

HY-161343

HDL-16	P2Y Receptor Necroptosis	Inflammation/Immunology
HDL-16 is a potent P2Y₁₄R antagonist with an IC₅₀ of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function .

HY-118173

Nephrin Hopane-6α,7β,22-triol	Others	Metabolic Disease
Nephrin (Hopane-6α,7β,22-triol) is a cell surface signaling receptor protein with activity in regulating podocyte function. Nephrin plays an important role in the normal function of the kidney's filtration barrier. Nephrin is associated with beta cell survival signals and helps maintain cell survival. Urinary levels of nephrin may be associated with tubular injury and can serve as a biomarker for early acute kidney injury .

HY-144604

FPR2 agonist 2	Formyl Peptide Receptor (FPR)	Infection Neurological Disease
FPR2 agonist 2 is a potent and permeates the blood?brain barrier FPR2 agonist with an EC₅₀ of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity .

HY-163565

BIIB129	Btk	Neurological Disease
BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells. BIIB129 can be used in multiple sclerosis (MS) research .

HY-W717504

Glucosylceramide, plant	Others
Glucosylceramide, plant is a plant-derived glycolipid with anti-inflammatory and immunomodulatory activities. Glucosylceramide, plant plays an important role in promoting cell proliferation and repair. Glucosylceramide, plant is widely used in skin care products to enhance skin barrier function. Glucosylceramide, plant has also been studied for improving nervous system health, showing potential neuroprotective effects.

HY-141899

MK-6884	mAChR	Neurological Disease
MK-6884 is a M4 muscarinic receptor positive allosteric modulator (PAM) with a K_i value of 0.19 nM. MK-6884 can be used for the research of the neurodegenerative diseases. MK-6884 can be conveniently radiolabeled with carbon-11 and as a positron emission tomography (PET) imaging agent .

HY-168028

mGluR2 modulator 5	mGluR	Neurological Disease
mGluR2 modulator 5 (Compound 11) is an orally active, selective mGluR2 negative allosteric modulator with an IC₅₀ of 8.9 nM. Pharmacokinetic studies in rats show that mGluR2 modulator 5 can effectively cross the blood-brain barrier. It can modulate cognitive and neurological functions in mood disorders and is suitable for research in the field of neurodegenerative diseases .

HY-16485

Telavancin hydrochloride TD-6424 hydrochloride	Antibiotic Bacterial	Infection
Telavancin hydrochloride is the hydrochloride form of Telavancin (HY-112959). Telavancin hydrochloride is a semisynthetic derivative of vancomycin, and exhibits antibacterial efficacy through inhibition of cell wall synthesis and disruption of cell membrane barrier function. Telavancin hydrochloride is efficient against antibiotic resistant S. aureus strains MRSA, VISA, and hVISA. Telavancin hydrochloride attenuates gram positive bacteria induced complicated skin and skin structure infections (cSSSI) .

HY-N0729S1

Linoleic acid-d11	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Linoleic acid-d₁₁ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S

Linoleic acid-d4	Isotope-Labeled Compounds Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Linoleic Acid-d₄ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S2

Linoleic acid-13C18	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Linoleic acid- ¹³C₁₈ is the ¹³C labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S3

Linoleic acid-13C1	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Linoleic acid- ¹³C₁ is the ¹³C labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S5

Linoleic acid-d2 Deulinoleic acid	Endogenous Metabolite	Metabolic Disease
Linoleic Acid-d₂ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .

HY-N0729S4

Linoleic acid-d5	Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Linoleic Acid-d₅ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .

HY-169022

4-FPBUA	Autophagy mTOR	Neurological Disease
4-FPBUA is a semisynthetic analog of usnic acid (HY-W015883) that can enhance cellular blood-brain barrier (BBB) function and increase the transport of Amyloid β (Aβ) across monolayer cells. 4-FPBUA is also an inhibitor of mTOR, capable of enhancing cellular Autophagy, thereby reversing BBB disruption in vivo and being utilized in research for Alzheimer's disease .

HY-161620

DW18134	IRAK	Inflammation/Immunology
DW18134 is an inhibitor for interleukin receptor-associated kinase 4 (IRAK 4) with an IC₅₀ of 11.2 nM. DW18134 inhibits phosphorylation of IRAK4 and IKK, downregulates the secretion of TNF-α and IL-6. DW18134 attenuates the Lipopolysaccharides (HY-D1056)-induced peritonitis and DSS-induced colitis in mouse models, and protects the intestinal barrier function .

HY-16969

Dihexa 5 Publications Verification PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH2	c-Met/HGFR	Neurological Disease
Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (K_d=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease .

HY-116673

TTK21	Histone Acetyltransferase	Neurological Disease
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .

HY-125469

ICA-105665 PF-04895162	Potassium Channel	Neurological Disease
ICA-105665 (PF-04895162) is a potent and orally active neuronal Kv7.2/7.3 and Kv7.3/7.5 potassium channels opener. ICA-105665 inhibits liver mitochondrial function and bile salt export protein (BSEP) transport (IC₅₀ of 311 μM). ICA-105665 can penetrate the blood-brain barrier and has antiseizure effects .

HY-144825

Chol-CTPP	Apoptosis Reactive Oxygen Species	Cancer
Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function .

HY-17623

Tegoprazan 2 Publications Verification CJ-12420; RQ-00000004	Proton Pump Potassium Channel Na+/K+ ATPase	Inflammation/Immunology
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H ⁺/K ⁺-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H ⁺/K ⁺-ATPase with IC₅₀ values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

HY-P99917

Eflepedocokin alfa	STAT	Inflammation/Immunology
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .

HY-131688

2-Chlorohexadecanoic acid	Others	Inflammation/Immunology
2-Chlorohexadecanoic acid, an inflammatory lipid mediator, interferes with protein palmitoylation,induces ER-stress markers, reduced the ER ATP content, and activates transcription and secretion of IL-6 as well as IL-8.2-Chlorohexadecanoic acid disrupts the mitochondrial membrane potential and induces procaspase-3 and PARP cleavage.2-Chlorohexadecanoic acid can across blood-brain barrier (BBB) and compromises ER- and mitochondrial functions in the human brain endothelial cell line hCMEC/D3 .

HY-148030

XL01126	PROTACs LRRK2	Neurological Disease
XL01126 is a potent LRRK2 PROTAC (DC₅₀: 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2)) composed of the VHL ligand VH 101, thiol (HY-47851, blue part) and the LRRK2 inhibitor HG-10-102-01 (HY-13488, red part). XL01126 crosses the blood-brain barrier and is used as a degradation probe in Parkinson's disease research. XL01126 can be used to study the non-catalytic and framework functions of LRRK2 .

HY-17623S

Tegoprazan-d6 CJ-12420-d₆; RQ-00000004-d₆	Proton Pump Na+/K+ ATPase	Metabolic Disease
Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

HY-163879

hMAO-B-IN-9	Monoamine Oxidase Reactive Oxygen Species Ferroptosis	Neurological Disease
hMAO-B-IN-9 (Compound 25c) is a non-competitive inhibitor for monoamine oxidase B (MAO-B) with an IC₅₀ of 1.58 µM (hMAO-B). hMAO-B-IN-9 forms complex with iron ions as a chelator, and inhibits Erastin (HY-15763)-induced ferroptosis. hMAO-B-IN-9 exhibits antioxidant activity by downregulating the level of reactive oxygen species (ROS). hMAO-B-IN-9 improves cognitive function in mice, without significant toxicity (30 mg/kg). hMAO-B-IN-9 is blood-brain barrier permeable, according to the in silico prediction .

HY-135167

HOCPCA	Others	Neurological Disease
HOCPCA is a compound with neuroprotective activity that improves sensorimotor function in mice after experimental stroke. HOCPCA selectively binds to the CaMKIIα hub domain, modulates signaling of different CaMKII pools, and alleviates abnormal CaMKII signaling after cerebral ischemia. HOCPCA promotes hippocampal neuronal activity and enhances working memory. HOCPCA also normalizes Thr286 autophosphorylation in the cytoplasm after ischemia and downregulates ischemia-specific expression of active CaMKII enzymatic cleavage fragments. HOCPCA binds to the GHB binding site with 27-fold higher affinity than GHB and has good blood-brain barrier penetration ability .

HY-N0408R

Picroside II (Standard)	NF-κB Reactive Oxygen Species Apoptosis Influenza Virus	Infection Neurological Disease Inflammation/Immunology Cancer
Picroside II (Standard) is the analytical standard of Picroside II. This product is intended for research and analytical applications. Picroside II, an iridoid compound extracted from Picrorhiza, exhibits anti-inflammatory and anti-apoptotic activities. picroside II alleviates the inflammatory response in sepsis and enhances immune function by inhibiting the activation of NLRP3 inflammasome and NF-κB pathways . Picroside II is an antioxidant, exhibits a significant neuroprotective effect through reducing ROS production and protects the blood-brain barrier (BBB) after cerebral ischemia-reperfusion (CI/R) injury. Picroside II has antioxidant, anti-inflammatory, immune regulatory, anti-virus and other pharmacological activities .

Cat. No.	Product Name

HY-L028

CNS-Penetrant Compound Library	864 compounds
The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy. MCE offers a unique collection of 864 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

CNS-Penetrant Compound Library

864 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 864 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

Cat. No.	Product Name	Target	Research Area

HY-148195

NNZ 2591	Peptides	Neurological Disease
NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome .

HY-P2634

Acetyl pentapeptide-1	Peptides	Metabolic Disease
Acetyl pentapeptide-1 is a pentapeptide. Acetyl pentapeptide-1 combined with other oligopeptides can enhance the skin barrier function.

Cat. No.	Product Name	Target	Research Area

HY-P99403

Refanezumab GSK249320	Inhibitory Antibodies	Neurological Disease
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke .

HY-P99917

Eflepedocokin alfa	STAT	Inflammation/Immunology
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .

Linoleic acid 10+ Cited Publications	Cardiovascular Disease Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Endocrine diseases Endogenous metabolite Disease Research Fields Biological Pesticide Research Agricultural Research	Endogenous Metabolite
Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .

Cat. No.	Product Name	Chemical Structure

HY-N0729S

Linoleic acid-d4

Linoleic Acid-d₄ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S2

Linoleic acid-13C18

Linoleic acid- ¹³C₁₈ is the ¹³C labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S4

Linoleic acid-d5

Linoleic Acid-d₅ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .

HY-N0729S1

Linoleic acid-d11

Linoleic acid-d₁₁ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S3

Linoleic acid-13C1

Linoleic acid- ¹³C₁ is the ¹³C labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism [1][2].

HY-N0729S5

Linoleic acid-d2

Linoleic Acid-d₂ is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .

HY-17623S

Tegoprazan-d6

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks